RSV Seasonal Vaccine Introduction and Growth Strategy
68 potential new vaccines and medicines in pipeline
Phase II -19 assets
Infectious diseases
HIV (VIIV)
Respiratory/Immunology
Oncology
Opportunity driven
3437949
4406371
3536852
3528869
4023393
4178116
5101956
5101955
4106647
4348413
3036656
sanfetrinem cilexetil (GV118819)
BVL-GSK098
VIR-2482
3810109
Benlysta (belimumab)
3858279
belrestotug (4428859)
4532990
Recombinant protein, adjuvanted*
Live, attenuated
GMMA*
Viral vector with recombinant protein, adjuvanted*
Recombinant protein, OMV, conjugated vaccine
Live, attenuated
MAPS*
MAPS*
Recombinant protein, adjuvanted*
GMMA
Leucyl t-RNA synthetase inhibitor*
Serine beta lactamase inhibitor*
Ethionamide booster*
Neutralizing monoclonal antibody*5
Broadly neutralizing antibody*
Anti-BLys antibody
Anti-CCL17 antibody*
Anti-TIGIT antibody*
HSD17B13 siRNA*
Shigella
Malaria fractional dose
MMRV new strain
Therapeutic hepatitis B virus¹**
MenABCWY, 2nd Gen
Varicella new strain
Adult pneumococcal disease, 24-valent
Paediatric pneumococcal disease, 24-valent
Human papillomavirus
Gonorrhea¹
Tuberculosis
Tuberculosis
Tuberculosis
Influenza
HIV
Systemic sclerosis associated interstitial lung disease
Osteoarthritis pain**7
Non-small cell lung cancer
Non-alcoholic steatohepatitis
GSK
*In-license or other alliance relationship with third party
**
Additional indications or candidates also under investigation In registration
1. In phase I/II study 2. Transition activities underway to enable further progression by partner 3. GSK has an exclusive global license option to co-develop and commercialise the candidate 4. Imminent study start 5. GSK has
exclusive option to co-develop post phase II 6. Phase II/III study start expected in 2023 7. Phase II study start expected in 2023 8. Approved in US and EU 9. Phase III study start expected in 2023 10. Phase III trial in patients
with progranulin gene mutation
38View entire presentation